SCHEMBL3950787

SCHEMBL3950787

Cc1cc(-c2c(Cl)cccc2Cl)nc(N)n1

nearest known ligand 0.79

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 12/20 0.79
HSP90AB1 P08238 8/20 0.59
NR4A2 P43354 1/20 0.47
PTPN1 P18031 1/20 0.46
KCNH2 Q12809 1/20 0.45
NUDT1 P36639 1/20 0.44
SRC P12931 1/20 0.43
MAPT P10636 1/20 0.42
NPC1 O15118 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C19 P33261 1/20 0.41
RAB9A P51151 1/20 0.41
AURKA O14965 1/20 0.41
PDPK1 O15530 1/20 0.41
TGFBR1 P36897 1/20 0.41
ROCK1 Q13464 1/20 0.41
AURKB Q96GD4 1/20 0.41
CRHR1 P34998 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3951578 0.86 HSP90AA1 (1.00) HSP90AA1HSP90AB1NR4A2KCNH2NPC1
SCHEMBL3945239 0.83 HSP90AA1 (0.61) HSP90AA1HSP90AB1NUDT1SRCCYP1A2
SCHEMBL3946470 0.79 HSP90AA1 (0.56) HSP90AA1HSP90AB1KCNH2CYP1A2AURKA
SCHEMBL3952648 0.76 HSP90AA1 (0.81) HSP90AA1HSP90AB1KCNH2NPC1RAB9A
SCHEMBL5747382 0.76 HSP90AA1 (0.58) HSP90AA1HSP90AB1AURKAPDPK1TGFBR1
SCHEMBL14359627 0.76 HSP90AA1 (0.75) HSP90AA1HSP90AB1NUDT1MAPTCYP1A2
SCHEMBL5750542 0.74 HSP90AA1 (0.56) HSP90AA1HSP90AB1KCNH2MAPTNPC1
SCHEMBL22501986 0.73 HSP90AA1 (0.66) HSP90AA1HSP90AB1
SCHEMBL6813816 0.72 ADORA2A (0.73) HSP90AA1HSP90AB1MAPTNPC1CYP1A2
SCHEMBL1358738 0.71 RAB9A (0.61) HSP90AA1NPC1RAB9AAURKAPDPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090215777-A1 Pyrimidine Derivatives As HSP90 Inhibitors ASTEX THERAPEUTICS LTD. (GB) 2009-08-27 US disclosed
US-20090215777-A1 Pyrimidine Derivatives As HSP90 Inhibitors ASTEX THERAPEUTICS LTD. (GB) 2009-08-27 US disclosed
US-20090215777-A1 Pyrimidine Derivatives As HSP90 Inhibitors ASTEX THERAPEUTICS LTD. (GB) 2009-08-27 US disclosed
EP-2049497-A2 PYRIMIDINE DERIVATIVES AS HSP90 INHIBITORS Astex Therapeutics Limited (GB) 2009-04-22 EP disclosed
WO-2006123165-A2 PYRIMIDINE DERIVATIVES AS HSP90 INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215777-A1 Pyrimidine Derivatives As HSP90 Inhibitors HSP90AB1, HSP90AB2P, HSP90B1 HSP90AA1 4/4885HSP90AB1 1/4885NR4A2 543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.